Sage Journals: Discover world-class research

Abstract

Multiple sclerosis is a chronic disabling neurological disease due to an autoimmune process of unknown cause. It is characterized by the formation of patches of demyelination (plaques) throughout the brain and spinal cord. There is no peripheral nerve involvement.

Get full access to this article

View all access options for this article.

References

Casetta

Iuliano

Filippini

Azathioprine for multiple sclerosis. Cochrane Database of Systematic Reviews (2007) Issue 4: Art No.:CD003982. DOI: 10.1002/14651858.CD003982.pub2.

Department of Health Cost effective provision of disease modifying therapies for people with multiple sclerosis (HSC 2002/004) (2002) Accessed via www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/DH_4004332 [date last accessed 16.01.2009].

Department of Health National service framework for long-term conditions (2005) Accessed via www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105361 [date last accessed 16.01.2009].

DVLA At a glance guide to the current medical standards of fitness to drive (2008) Accessed via www.dvla.gov.uk/media/pdf/medical/aagv1.pdf [date last accessed 16.01.2009].

Farinotti

Simi

Di Pietrantonj

Dietary interventions for multiple sclerosis. Cochrane Database of Systematic Reviews (2007) Issue1: Art No.: CD004192. DOI: 10.1002/14651858.CD004192.pub2.

Multiple Sclerosis Society. A guide to MS for GPs and primary care teams (2006) Accessed via www.mssociety.org.uk/downloads/Guide_to_MS_for_GPsv2-renumber.879f82b2.pdf [date last accessed 16.01.2009].

Multiple Sclerosis Trust/Royal College of Nursing/Royal College of Physicians. Multiple sclerosis—Commissioning pathway for 18 weeks and long-term condition management (2008) Accessed via www//author.pathwaysforhealth.org/xpath2007/xeditor/publisher.asp?d_ref=17538D65C6FF442B93F54AFAFB0791BD&d_name=&o_mode=0 [date last accessed 16.01.2009].

NICE Depression: Management of depression in primary and secondary care (2004) Accessed via www.nice.org.uk/nicemedia/pdf/CG23fullguideline.pdf [date last accessed 16.01.2009].

NICE/Royal College of Physicians. Diagnosis and management of multiple sclerosis in primary and secondary care (2004) Accessed via www.rcplondon.ac.uk/pubs/books/MS/MSfulldocument.pdf [date last accessed 16.01.2009].

10.

NICE. Referral guidelines for suspected cancer (2005) Accessed via www.nice.org.uk/nicemedia/pdf/CG027fullguideline.pdf [date last accessed 16.01.2009].

11.

NICE. Natalizumab for the treatment of adults with highly active relapsing — remitting multiple sclerosis (2007) Accessed via www.nice.org.uk/nicemedia/pdf/TA127Niceguidance.pdf [date last accessed 16.01.2009].

12.

Polman

C.H.

Reingold

S.C.

Edan

Diagnostic criteria for multiple sclerosis: revisions to the “McDonald Criteria”. Annals of Neurology (2005) 58 (6): p. 840–6.

13.

RCG Curriculum statement 15.7: Neurological problems. Accessed via www.rcgp-curriculum.org.uk/PDF/curr_15_7_Neurological_problems.pdf [date last accessed 16.01.2009].

14.

Simon

Oxford general practice library: Neurology (2006) Oxford: Oxford University Press ISBN: 978–0199298044.

15.

Zajicek

Fox

Sanders

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet (2003) 362: p. 1517–26.